| abstract |
This disclosure relates to Compound I which is in the form of a crystalline solid of a stimulant of soluble guanylate cyclase (sGC). Methods for preparing these solid forms are also provided herein. The present invention also relates to pharmaceutical formulations and dosage forms and uses thereof comprising these solid forms alone or in combination with one or more additional agents, for the treatment and / or prevention of various diseases or disorders; These diseases or disorders can benefit from sGC stimulation or from increased concentrations of nitric oxide (NO) and / or cyclic guanosine monophosphate (cGMP). |